Tumor-on-chip modeling of organ-specific cancer and metastasis.

Autor: Del Piccolo N; Department of Biomedical Engineering, University of California, Davis, One Shields Ave, Davis, CA 95616, United States., Shirure VS; Department of Biomedical Engineering, University of California, Davis, One Shields Ave, Davis, CA 95616, United States., Bi Y; Department of Surgery, The Alvin J. Siteman Cancer Center, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110-1010, United States., Goedegebuure SP; Department of Surgery, The Alvin J. Siteman Cancer Center, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110-1010, United States., Gholami S; Department of Surgery, University of California, Davis, 2335 Stockton Boulevard, Sacramento, CA 95817, United States., Hughes CCW; Department of Molecular Biology & Biochemistry and Department of Biomedical Engineering, University of California, Irvine, CA 92697-3900, United States., Fields RC; Department of Surgery, The Alvin J. Siteman Cancer Center, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110-1010, United States., George SC; Department of Biomedical Engineering, University of California, Davis, One Shields Ave, Davis, CA 95616, United States. Electronic address: scgeorge@ucdavis.edu.
Jazyk: angličtina
Zdroj: Advanced drug delivery reviews [Adv Drug Deliv Rev] 2021 Aug; Vol. 175, pp. 113798. Date of Electronic Publication: 2021 May 18.
DOI: 10.1016/j.addr.2021.05.008
Abstrakt: Every year, cancer claims millions of lives around the globe. Unfortunately, model systems that accurately mimic human oncology - a requirement for the development of more effective therapies for these patients - remain elusive. Tumor development is an organ-specific process that involves modification of existing tissue features, recruitment of other cell types, and eventual metastasis to distant organs. Recently, tissue engineered microfluidic devices have emerged as a powerful in vitro tool to model human physiology and pathology with organ-specificity. These organ-on-chip platforms consist of cells cultured in 3D hydrogels and offer precise control over geometry, biological components, and physiochemical properties. Here, we review progress towards organ-specific microfluidic models of the primary and metastatic tumor microenvironments. Despite the field's infancy, these tumor-on-chip models have enabled discoveries about cancer immunobiology and response to therapy. Future work should focus on the development of autologous or multi-organ systems and inclusion of the immune system.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CCWH and SCG are co-founders and CCWH is the CSO of Aracari Biosciences, a company that is commercializing organ-on-chip technology through a patent licensing agreement with UCI. The terms of this arrangement are approved and monitored by the Conflict of Interest Committee at UCI (CCWH) and UC Davis (SCG). The remaining authors (NDP, VSS, YB, SPG, SG, RCF) have no declarations of interest.
(Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: